
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

SCHEDULE 14A INFORMATION

**Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934
(Amendment No.)**

Filed by the Registrant

Filed by a Party other than the Registrant

Check the appropriate box:

- Preliminary Proxy Statement
- Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))**
- Definitive Proxy Statement
- Definitive Additional Materials
- Soliciting Material Pursuant to §240.14a-12

FULCRUM THERAPEUTICS, INC.

(Name of Registrant as Specified in Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check all boxes that apply):

- No fee required.
 - Fee paid previously with preliminary materials.
 - Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11
-
-



P.O. BOX 8016, CARY, NC 27512-8903

Fulcrum Therapeutics, Inc. Important Notice Regarding the Availability of Proxy Materials

**Stockholders Meeting to be held on
June 8, 2023**

For Stockholders of record as of April 10, 2023

This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. This is not a ballot. You cannot use this notice to vote your shares. We encourage you to access and review all of the important information contained in the proxy materials before voting.

To view the proxy materials, and to obtain directions to attend the meeting, go to: www.proxydocs.com/FULC

To vote your proxy while visiting this site, you will need the 12 digit control number in the box below.

Under United States Securities and Exchange Commission rules, proxy materials do not have to be delivered in paper. Proxy materials can be distributed by making them available on the internet.



**For a convenient way to view proxy materials and VOTE go to
www.proxydocs.com/FULC**

**Have the 12 digit control number located in the shaded box above available
when you access the website and follow the instructions.**

If you want to receive a paper or e-mail copy of the proxy material, you must request one. There is no charge to you for requesting a copy. In order to receive a paper package in time for this year's meeting, you must make this request on or before May 29, 2023.

To order paper materials, use one of the following methods.



INTERNET

www.investorelections.com/FULC



**TELEPHONE
(866) 648-8133**



*** E-MAIL**

paper@investorelections.com

When requesting via the Internet or telephone you will need the 12 digit control number located in the shaded box above.

* If requesting material by e-mail, please send a blank e-mail with the 12 digit control number (located above) in the subject line. No other requests, instructions OR other inquiries should be included with your e-mail requesting material.

Fulcrum Therapeutics, Inc.

Meeting Type: Annual Meeting of Stockholders

Date: Thursday, June 8, 2023

Time: 9:00 AM, Eastern Time

Place: Annual Meeting to be held live via the Internet -
please visit www.proxydocs.com/FULC for more details.

You must register to attend the meeting online and/or participate at www.proxydocs.com/FULC

SEE REVERSE FOR FULL AGENDA

Fulcrum Therapeutics, Inc.

Annual Meeting of Stockholders

FOR EACH OF THE NOMINEES LISTED IN PROPOSAL 1, FOR PROPOSAL 2, FOR PROPOSAL 3, AND FOR PROPOSAL 4.

PROPOSAL

1. To elect two Class I directors named below to a 3-year term expiring at the 2026 annual meeting of stockholders.
 - 1.01 Alan Ezekowitz
 - 1.02 Sonja Banks
2. To approve an amendment to the Company's 2019 Stock Incentive Plan to modify the automatic increase to the share reserve provision.
3. To approve an amendment to the Company's Restated Certificate of Incorporation to limit the liability of certain Company officers as permitted by recent amendments to Delaware law.
4. To ratify the appointment of Ernst & Young as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2023.
5. To consider and act upon such other business as may properly come before the meeting or any adjournment or postponement thereof.